Our hypothesis is that by obtaining in-depth knowledge of the molecular composition of PMP, treatment of this debilitating disease will be improved. The long-term goal of this research is therefore to provide cure for more patients with PMP, and for patients that cannot be cured, the goal is to search for drug targets and drugs that can inhibit tumor growth to prevent disease progression and alleviate symptoms.

In the Cure4PMP project we will analyze a substantial number of PMP samples to identify clinically useful molecular biomarkers therapeutic targets. A challenge is that many samples contain a lot of mucin, but very few tumor cells, and in the first part of the project we have tested methods for analysis of such samples. Using targeted deep sequencing we have been able to identify mutations in samples with very low tumor cell count, completing this task. The results will be presented at the 10th International congress on Peritoneal Surface Malignancies in Washington in November 2016.